Merck's Anti-TL1A Therapy Beats Main Goal in Ulcerative Colitis Trial

SentiSense · Published · Updated

Merck's anti-TL1A antibody, developed after the Prometheus acquisition, met primary and key secondary endpoints in a Phase 3 study for ulcerative coli...

Sign in to read the full story. Free accounts include 20 full reads a month.

Sign in or create a free account

Powered by SentiSense - Intelligent Market Analysis